Calcitonin is a peptide hormone consisting of 32 amino acid residues and the calcitonin receptor is a Class B G protein-coupled receptor (GPCR). The crystal structure of the human calcitonin receptor ectodomain (CTR ECD) in complex with a truncated analogue of salmon calcitonin ([BrPhe 22 ]sCT(8 -32)) has been determined to 2.1-Å resolution. Parallel analysis of a series of peptide ligands showed that the rank order of binding of the CTR ECD is identical to the rank order of binding of the fulllength CTR, confirming the structural integrity and relevance of the isolated CTR ECD. The structure of the CTR ECD is similar to other Class B GPCRs and the ligand binding site is similar to the binding site of the homologous receptors for the calcitonin gene-related peptide (CGRP) and adrenomedulin (AM) recently published (Booe, J. M., Walker, C. . (2015) Mol. Cell 58, 1040 -1052) . Interestingly the receptor-bound structure of the ligand [BrPhe 22 ]sCT(8 -32) differs from the receptor-bound structure of the homologous ligands CGRP and AM. They all adopt an extended conformation followed by a C-terminal ␤ turn, however, [BrPhe 22 ]sCT(8 -32) adopts a type II turn (Gly 28 -Thr 31 ), whereas CGRP and AM adopt type I turns. Our results suggest that a type II turn is the preferred conformation of calcitonin, whereas a type I turn is the preferred conformation of peptides that require RAMPs; CGRP, AM, and amylin. In addition the structure provides a detailed molecular explanation and hypothesis regarding ligand binding properties of CTR and the amylin receptors.
Calcitonin (CT) 3 is a peptide hormone that possesses the ability to lower the calcium plasma concentration (1) . CT is predominantly produced in C cells of the thyroid gland and it is secreted upon increases in the serum calcium concentration preventing hypercalcemia. Salmon CT (sCT) has been utilized for 40 years as a therapeutic agent for treatment of metabolic bone diseases such as osteoporosis and Paget's disease, due to its high potency; 40 -50 times higher compared with human CT. The calcitonin family of peptides also comprises amylin, adrenomedullin (AM), and two calcitonin gene-related peptides (␣-CGRP and ␤-CGRP) (2) . These peptides all have an amino-terminal disulfide bond connecting residues 1 and 7 (residues 2 and 7 for amylin), a stretch of amphipathic ␣-helix, and an amide at the carboxyl-terminal residue.
The CT receptor (CTR) is a Class B G protein-coupled receptor (GPCR) and it is expressed in many different cell types and tissues (3) . Class B GPCRs are characterized by having a large ectodomain (ECD) of 100 -160 amino acid residues with a conserved tertiary structure stabilized by three conserved disulfide bridges. The ECD binds the carboxyl-terminal region of the peptide ligand and thereby positions the amino-terminal part of the ligand for binding to the transmembrane domain to initiate signaling, a mechanism referred to as the two-domain binding model (reviewed in Ref. 4 ). The structures of several Class B GPCR ECDs in complex with and without ligands have been determined including the ECDs of corticotropin-releasing factor receptor (5) , pituitary adenylate cyclase-activating polypeptide receptor (6) , glucose-dependent insulinotropic polypeptide receptor (7) , parathyroid hormone-1 receptor (8) , glucagon-like peptide-1 receptor (9) , calcitonin receptor-like receptor (CLR) (10) , and the glucagon receptor (11) . The crystal structures of the transmembrane domains of the glucagon receptor (12) and the type 1 corticotropin releasing factor receptor (13) were determined recently but the structure of a full-length Class B receptor remains to be determined.
The pharmacology of the CT family of peptides is complex due to heterodimerization of CTR or CLR with a membranebound receptor activity-modifying protein (RAMP). There are three different variants of RAMPs: RAMP-1, RAMP-2, and RAMP-3, which have ϳ30% amino acid sequence identity and the ligand specificity of CTR and CLR is determined by the interaction (or not) with the RAMPs. CTR is on its own the receptor for CT, whereas in combination with RAMP-1 or RAMP-3 it changes ligand specificity and becomes the amylin receptor (14, 15) . The heterodimer of CLR and RAMP-1 is the receptor for CGRP, whereas the heterodimer of CLR and RAMP-2 or RAMP-3 are the receptors for AM. Previously, crystal structures of the CLR ECD in complex with the RAMP-1 ECD have been determined, both as a heterodimer and as ternary complexes with two different small molecule receptor antagonists (10) . More recently, the crystal structures of the peptide ligand-bound CGRP receptor ECD (CLR/RAMP-* The authors declare that they have no conflicts of interest with the contents of this article. The atomic coordinates and structure factors (code 5II0) have been deposited in the Protein Data Bank (http://wwpdb.org/). 1ECD) and AM receptor ECD (CLR/RAMP-2ECD) were published (16) . These structures provided the first molecular insights into ligand binding and specificity of this subclass of Class B GPCRs. The molecular details that govern ligand binding and specificity of CTR have not previously been clarified by high resolution structure determination. Likewise the change of ligand specificity of CTR enforced by the interaction with RAMP is not fully understood. In this study we determined the crystal structure of the CTR ECD in complex with the peptide ligand [BrPhe 22 ]sCT8 -32 ([BrPhe 22 ] ϭ 4-bromo-L-phenylalanine at position 22). The molecular details of the interaction between sCT and the CTR ECD is revealed by the structure and provides new information regarding the structure of sCT in the receptor-bound state and the molecular determinants of ligand specificity of this Class B receptor subclass, in particular the receptors for calcitonin and amylin.
Experimental Procedures
Peptide Synthesis-Human calcitonin was acquired from Sigma (H-2250). All other peptides were synthesized on a Liberty (CEM) or a Prelude (PTI) synthesizer by standard Fmoc chemistry on Rink-AM or Rink-ChemMatrix resins using Fmoc-amino acids with standard protecting groups, diisopropylcarbodiimide/HOAt for coupling, and 20% piperidine for deprotection. For the peptides with a disulfide bond, Cys was incorporated as Fmoc-Cys(Trt)-OH, and after completion of the synthesis, the disulfide was formed on-resin by treatment with an excess of 1% iodine in N-methylpyrrolidone for 15 min. Cleavage was performed with trifluoroacetic acid/water/triisopropylsilane (95:2.5:2.5) for 1 h followed by precipitation with diethyl ether. The peptides were purified by RP-HPLC on a C18 column in TFA-acetonitrile and characterized by LC-MS and UPLC.
Cloning, Expression, and Refolding of CTR ECD-An oligonucleotide sequence encoding the 120-aa ECD part of the human CTR (Isoform II) was designed, codon optimized for expression in Escherichia coli, and ordered from GeneArt (GmbH Germany). A His 6 purification tag was introduced in the amino-terminal of the CTR ECD sequence using PCR with forward and reverse oligonucleotide primers, to introduce NdeI/BamHI restriction enzyme sites. The PCR product was ligated into a TOPOBlunt-End vector (Invitrogen) according to the manufacturer's instructions and the sequence was verified by DNA sequencing (DNA Technology). The NdeI/BamHI fragment comprising His 6 -CTR ECD was ligated into a pET11a E. coli expression vector (pACSH438)(Novagen) resulting in fusion protein with the following sequence: MGSSHHHHHH-SSGLVPRGSAFSNQTYPTIEPKPFLYVVGRKKMMDAQYK-CYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGV-LSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRT-WSNYTMCNAFTPEKLKN. Due to the location of the thrombin cleavage site (underlined), two residues, Gly-Ser, were introduced in the amino terminus of the CTR ECD. E. coli BL21(DE3) were transfected with pACSH438 and plated on AMP containing LB Agar plates to obtain the expression strain (eMD712). Expression in a 1-liter shaker flask was performed using LB medium with 100 mg/ml of AMP for 3 h at 37°C and using 0.5 mM isopropyl 1-thio-␤-D-galactopyranoside and expression of a 14-kDa insoluble protein corresponding to His 6 -CTR ECD was verified using Coomassie-stained SDS-PAGE gels.
Strain emD712 was propagated on a solid agar surface (LBagar ϩ 100 mg/liter of AMP) at 30°C overnight. A 10-liter fed-batch fermentation was subsequently performed in a 20-liter stainless steel bioreactor using a complex medium with glycerol feeding according to a predefined feeding profile ensuring glycerol-limited growth. Throughout the fermentation, pH was kept at 6.9 by titration of 10% H 3 PO 4 and 10% NH 4 OH, and the temperature was controlled at 37°C. The culture was aerated at a flow of 2 vessel/volume/min of air and a backpressure of 0.3-0.45 bar. After 16 h of elapsed fermentation time, at A 600 of around 50, isopropyl 1-thio-␤-D-galactopyranoside (0.5 mM) was added to induce expression of His 6 -CTR ECD. Approximately 6 h after induction, the fermentation was terminated. The final biomass concentration was A 600 ϭ 80.5 or 30.65 g/liter cell dry weight. The culture broth was directly homogenized at 1500 bar at a single pass through the APV2000 high-pressure homogenizer. A total of 253 g of inclusion bodies were sedimented by centrifugation of the homogenate for 40 min at 4500 rpm (6056 ϫ g) and 4°C.
The CTR ECD inclusion bodies were isolated, denatured, and refolded as previously described for the glucagon-like peptide 1 receptor ECD (17) . The refolded protein was purified using Ni 2ϩ affinity chromatography using the following procedure: 1) buffer exchange using a Sephadex G25 XK 50/100 column running in binding buffer (20 mM Tris, pH 7.5, 0.1 M Na 2 SO 4 , 0.1 M L-Arg, 20 mM imidazole); 2) Ni 2ϩ affinity chromatography using a 5-ml HisTrap column eluted in 20 mM Tris, pH 7.5, 0.1 M Na 2 SO 4 , 0.1 M L-Arg, 500 mM imidazole; and 3) buffer exchange using a Sephadex G25 XK 50/100 column running in binding buffer. For binding studies the protein was further purified by size exclusion chromatography (SEC) using a Superdex 75 26/60 column running in 10 mM Tris, pH 7.5, 0.1 M Na 2 SO 4 , 2% glycerol. For structural studies the amino-terminal His tag was cleaved off by thrombin and the protein was further purified by ligand affinity chromatography as follows: 1) the ligand-affinity column was prepared by loading a biotinylated analogue of sCT onto a streptavidin column (HiTrap Streptavidin HP) and equilibrated in 10 mM Tris, pH 7.5, 0.1 M Na 2 SO 4 , 2% glycerol; 2) 10 mg of CTR ECD was loaded on the ligandaffinity column and equilibrated in 20 mM Tris, pH 7.5, 50 mM NaCl; and 3) the nCTR ECD was eluted in a ligand-bound form by loading of the ligand [BrPhe 22 ]sCT (8 -32) , at a high concentration (500 M) resulting in an excess of free ligand in the eluted sample. All columns were from GE Healthcare. The eluted sample was prone to aggregate at temperatures higher than 4°C and was hard to concentrate without massive precipitation. The addition of freshly prepared urea to a final concentration of 2 M solved the solubility problem and this protein solution was concentrated on an ultrafiltration centrifugation device with 3000-kDa cutoff to 10 mg/ml.
Binding to the Human CTR (Whole Cell Binding)-The binding assay was performed using a BHK cell line stably transfected with the human CTR, and a CREB-binding protein-responsive luciferase reporter gene. The day before the assay the cells were seeded into poly-D-lysine-coated 384W Opaque White, BD BioCoat plates (10000 cells/well) and incubated overnight at 37°C, 5% CO 2 , 95% humidity. Then, the cells were washed in Hanks' balanced salt solution (4°C), and incubated overnight at 4°C in a binding buffer containing test compounds, 25 pM 125 I-sCT (PerkinElmer Life Sciences, catalog number NEX423), a calcitonin, Dulbecco medium without phenol red (500 ml) (Gibco, 11880-028), 0.1% ovalbumin (5 ml of 10% ovalbumin) (Sigma number A5503), 10 mM Hepes (5 ml, 1 M) (Gibco number 15630-056) 1ϫ glutamine (5 ml, ϫ100) (Gibco number 35050087) 1% penicillin-streptomycin (5 ml, 100%) (Gibco number 15140-122), Complete (1 tablet/50 ml) (Roche number 5056489001) 0.1% Pluronic F68 (Gibco number 24040-032). The morning after, the plates were washed three times in Hanks' balanced salt solution (4°C), and lysed in Lysis buffer (0.1 M NaOH (VWR number 1.09136.1000), 1% SDS (Cayman Chemical Company number 600216). Then MicroScint40 was added and the plates were shaken at 500 rpm for a short period. The plate was then incubated at room temperature in the dark for 1 h and read on a TopCounter. The IC 50 was calculated using (one site binding competition analysis) GraphPad Prism5.
Binding to CTR ECD-Binding to the CTR ECD was assessed in a bead-based proximity assay (AlphaScreen) with His 6 -CTR ECD binding to Ni Chelate Acceptor beads and biotinylated sCT binding to Streptavidin Donor Beads (PerkinElmer, catalog number 6760619C). When biotinylated sCT binds to His 6 -CTR ECD, acceptor and donor beads are brought close together and a signal is created. The binding of compounds to CTR ECD was assessed indirectly by the ability to displace binding between CTR ECD and biotinylated sCT. The CTR ECD, biotinylated sCT, and compounds were diluted in buffer containing 25 mM Hepes, 0.1 M NaCl, 0.1% BSA (Sigma A-7888), pH 7.4. 5 l of compound, 5 l of CTR ECD (final concentration 10 nM), and 5 l of biotinylated sCT (final concentration 10 nM) was added per well in a 384-well plate and the plate incubated for 1 h at room temperature. 5 l of acceptor beads (final concentration 20 g/ml) and 5 l of donor beads (final concentration 20 g/ml) were added to the wells and the plate was incubated at 4°C overnight. The plate was read on Envision and results drawn using GraphPad Prism.
Crystallization and Diffraction Data Collection-Crystals of the CTR ECD⅐[BrPhe 22 ]sCT(8 -32) complex were grown at 18°C using sitting drop vapor diffusion, mixing equal volumes of protein (10 mg/ml of protein complex in 20 mM Tris, pH 7.5, 50 mM sodium chloride, 2 M urea) and precipitant (0.1 M Hepes, pH 7.5, 4.3 M sodium chloride). The crystal was cooled in liquid nitrogen using a cryoprotectant consisting of a 1:4 (v/v) mixture of ethylene glycol and precipitant. Diffraction data were collected at 100 K on a CCD detector from MAR Research using a MicroMax TM -007 HF x-ray generator. Autoindexing, integration, and scaling were performed using the HKL suite (18) .
Structure Determination and Refinement-Molecular replacement with PHASER (19) , implemented in the program suite PHENIX (20) , was performed using the ECD of the CLR from PDB entry 3N7S, chain A (10), as search model. A solution with three CTR ECD chains in the asymmetric unit was found, the side chains were altered to the CTR ECD amino acid sequence and the structure was further refined and model built using PHENIX and COOT (21) , respectively. For each CTR ECD molecule, there was a clear difference electron density for amino acid residues from the [BrPhe 22 ]sCT (8 -32) peptide that could be model built (residues 21-32 in two of the chains and residues 24 -32 in the third). All graphical illustrations of structures were made using PyMol (Schrödinger). The coordinates and the structure factors have been deposited in the PDB with accession number 5II0.
Modeling of CTR ECD Bound Antagonistic Peptide sCT (8 -32 )-A hybrid model of the CTR ECD-bound antagonistic peptide sCT (8 -32) was made by combining residues 8 -23 from a sCT NMR structure (PDB entry 2GLH (31)) and residues 24 -32 from [BrPhe 22 ]sCT(8 -32) (chain D in this work). The angle between the two peptide parts was chosen so that Val 8 from sCT approaches Met 49 of CTR.
Calculation of Interaction Areas-The area covered on the GPCR Class B ECDs due to binding of their respective peptide ligands were calculated for the CTR ECD⅐[BrPhe 22 ]sCT(8 -32) (chain A and D), corticotropin-releasing factor receptor 2␣ ECD⅐urocortin 1 (PDB entry 3N96, chain A and G), CLR⅐AM (PDB entry 4RWF, chains A and B), and glucagon-like peptide-1 receptor ECD⅐glucagon-like peptide-1 (PDB entry 3IOL, chain A and B) complexes. The program ArealMol from the CCP4 suite of programs (22) with a probe radius of 1.4 Å was used to calculate the total surface area of the receptor, A R , the total surface area of the ligand, A L , and the total surface area of the receptor⅐ligand complex, A RL . The interaction area was calculated as (A R ϩ A L Ϫ A RL )/2.
Results
Crystal Structure of the CTR ECD⅐[BrPhe22]sCT (8 -32) Complex-The crystal structure of the CTR ECD in complex with [BrPhe 22 ]sCT(8 -32) was determined and refined to 2.1-Å resolution ( Fig. 1a , statistics of the model are found in Table 1 ). The [BrPhe 22 ]sCT(8 -32) analogue was originally chosen for phasing of the crystal structure. This was not applicable, probably due to disorder of the 4-bromophenylalanine residue of the analogue, and molecular replacement was instead applied for phasing. The CLR ECD was used as the model for molecular replacement (CLR ECD PDB entry 3N7S, chain A only), and it shares ϳ60% amino acid residue sequence identity with the crystallized CTR ECD of this study. The overall structures of the CTR and CLR ECDs are very similar with a root mean square deviation of 1.03 Å for 92 aligned C␣ atoms as determined using default parameters in the program COOT (PDB code 3N7S chain A aligned with CTR ECD, chain A). The CTR ECD shares the fold with the other Class B GPCR ECD structures as illustrated in Fig. 2 . The structure of the ECD-bound [BrPhe 22 ]sCT (8 -32) is most similar to the structure of a CGRP analogue bound to the CLR⅐RAMP-1 ECD complex, which on the other hand is quite different from the structure of other receptor-bound peptides of Class B GPCRs, such as glucagonlike peptide-1, glucose-dependent insulinotropic polypeptide, and parathyroid hormone. The only secondary structure element of ECD-bound [BrPhe 22 ]sCT(8 -32) is a type II ␤ turn, which consists of residues Gly 28 -Thr 31 . Specifically, the backbone carbonyl oxygen of Gly 28 forms a hydrogen bond across the turn structure with the hydroxyl group of Thr 31 and the glycine residue at position 30 is compatible with the type II turn conformation (Fig. 3) .
The asymmetric unit contains three copies of the CTR ECD⅐[BrPhe 22 ]sCT(8 -32) complex with different numbers of disordered amino acid residues at the amino and carboxyl termini. The crystallized CTR ECD corresponds to residues 25-144 in the CTR isoform II sequence with a 2-amino acid residue (Gly-Ser) amino-terminal extension derived from the engineered thrombin cleavage site used as part of the protein production and the following residues were model built: CTR ECD residues 40 -138 (chain A), CTR ECD residues 34 -136 (chain B), CTR ECD residues 39 -138 (chain C), [BrPhe 22 ]sCT(8 -32) residues 21-32 (chain D), [BrPhe 22 ]sCT(8 -32) residues 24 -32 (chain E), and [BrPhe 22 ]sCT(8 -32) residues 21-32 (chain F). These complexes (chains AϩD, chains BϩE, and chains CϩF) are all very similar except from the amino-terminal residues of the CTR ECD (residues 34 -43), which considerably differ and so do [BrPhe 22 ]sCT(8 -32) residues 21-23 ( Fig. 1b) . Residues 41-43 from the C chain is forming a ␤ strand as part of a crystal packing interaction with the CTR ECD ␤ sheet of chain B. This crystal contact interaction probably explains the differences to chain A, where the same residues are part of a longer amino-terminal ␣ helix and in chain C these residues are disordered. The different conformations of these residues also propagates into the [BrPhe 22 ]sCT(8 -32) residues 21-23 conformation. All amino acid residues lies within the allowed regions of the Ramachandran plot and additional to these residues there are 293 water molecules (8 -32) ) and Trp 128 (CTR ECD). The type II ␤ turn formed by residues 28 -31 gives a complementary shape to the CTR ECD loop consisting of residues 121-128. Finally, the carboxyl-terminal prolineamide of the peptide ligand is forming a hydrogen bond to the carbonyl oxygen of residue Ser 129 of the CTR ECD, whereas the carbonyl oxygen at the carboxyl-terminal end of the ligand is involved in a hydrogen bond with the amide from the same Ser 129 in CTR ECD. This complementarity explains the necessity of the amino-terminal amide for ligand binding to the receptor. The carboxyl-terminal prolineamide (Pro 32 ) of [BrPhe 22 ]sCT(8 -32) stacks with Trp 79 of the CTR ECD. For comparison, the interaction surface of the peptide ligand and receptor ECD has been calculated for the complexes shown in Fig. 2 , b-e. The surfaces are of comparable size ranging from 586 Å 2 for glucagon-like peptide 1 in complex with its receptor ECD to 938 Å 2 for the AM⅐CLR ECD⅐RAMP-2 ECD complex with the [BrPhe 22 ]sCT(8 -32)⅐CTR ECD interaction surface being 603 Å 2 and 802 Å 2 for urocortin 1⅐corticotropinreleasing factor receptor 2␣ ECD.
Peptide Binding-To confirm that the binding property of the isolated CTR ECD was representative of the binding property of the full-length CTR, we analyzed a series of peptide ligands in parallel. Binding to the full-length receptor in a cellular environment was measured in a binding competition experiment on intact BHK cells stably transfected with the human CTR using 25 pM 125 I-sCT as the tracer ligand. In this assay all analogues were able to fully compete the binding of 125 I-sCT, with the following rank order sCT Ͼ sCT (8 - Fig. 4a ). To analyze the ability of the selected analogues to bind the CTR ECD, a bead-based proximity binding assay was established. As seen in Fig. 4b Fig. 4b ). These results confirmed that the binding property of the isolated CTR ECD used for the structural studies is representative of the binding property of the full-length CTR.
Discussion
The crystal structure presented here shows that sCT in the receptor-bound state forms a type II turn at the carboxyl terminus, which consists of the following residues: Gly 28 (i), Ser 29 (iϩ1), Gly 30 (iϩ2), and Thr 31 (iϩ3). Both hCT and sCT have a Gly in position iϩ2, which is typical of type II turns and therefore hCT probably also assumes a type II turn conformation. The different binding strength of sCT and hCT observed in this and previous studies is at least partially explained by the structure of [BrPhe 22 ]sCT (8 -32) bound to the CTR ECD. Several divergent residues in the carboxyl-terminal part of sCT and hCT are sensitive to Ala substitutions and these effects can be rationalized in the context of the new structural information, assuming a similar structure and binding mode of the two ligands (23) (Figs. 3 and 5a ). These are Thr 27 and Arg 24 , which are substituted by an Ile and Gln residue, respectively, in hCT 7), parathyroid hormone receptor in complex with parathyroid hormone-related protein (dark blue) (PDB 3C4M) (8), parathyroid hormone receptor in complex with parathyroid hormone (dark blue) (PDB 3H3G) (35) , glucagonlike peptide-1 receptor in complex with glucagon-like peptide-1 (dark blue) (PDB 3IOL) (36), corticotropin-releasing factor receptor 2␣ in complex with urocortin 1 (red) (PDB 3N96) (32) , and corticotropin releasing factor receptor 1 in complex with corticotropin-releasing factor (red) (PDB 3EHU) (5) . The codes within parentheses are the Protein Data Bank accession numbers of the displayed coordinates. b, full-length sequences of the peptide ligands of one representative from each binding mode where the part within 4 Å from their respective ECD are underlined. Carboxyl-terminal amide residues are marked by •. (Fig. 1c) . The Ile 27 residue in hCT does not have any side chain hydrogen binding potential and may even be repulsive and the Arg to Gln replacement at position 24 would possibly lead to a less favorable hydrogen bonding partner. Asn 26 is quite solvent exposed and may form an intramolecular hydrogen bond with the backbone amide of Gly 28 . A hydrophobic residue in this position, like Ala 26 of hCT, seems less favorable considering the lack of hydrogen bond potential and full solvent exposure of a hydrophobic residue. In the turn of sCT, the hydroxyl group of Ser 29 is facing away from the receptor and a hydrophobic residue in this position, like Val 29 of hCT, seems less favorable considering the hydrophilic surroundings of the receptor (His 121 , Glu 123 , and Asn 124 ). Finally, Thr 31 of sCT may form hydrogen bonds to both Gly 28 across the turn and the amide of the carboxyl-terminal prolineamide. The corresponding alanine residue in position 31 of hCT is unable to stabilize this particular conformation by hydrogen bonds. There are more amino acid sequence differences between sCT and hCT that may contribute to the difference in binding capability, but these are not observed in this crystal structure of the CTR ECD.
The solution structure of sCT has been studied by NMR in different solvents: 90% methanol (24), 90% trifluoroethanol (25) , and in sodium dodecyl sulfate micelles (26) . These structures all show an ␣-helical segment for residues 8 -22, whereas residues 23-32 are in an extended conformation reaching back to the ␣-helical part. In the structure of the ligand-bound CTR ECD presented here the corresponding ␣-helical fragment is not visible in the difference electron density map due to flexibility. It is, however, likely that an ␣-helix is formed by residues 8 -22 upon binding of sCT to the full-length CTR. The ␣-helix formation thereby defines the distances to correctly position the amino-terminal residues, including the disulfide bridge, which is necessary for receptor activation. Flexibility was also observed at the amino-terminal part of the receptor as indicated by different conformations in the three complexes of the asymmetric unit illustrated in Fig. 1b . It is, however, quite interesting to observe these possible conformations and to speculate on the impact of these different possibilities for the full-length receptor although it is not possible to judge the actual conformation(s) in the full-length CTR. Furthermore, the 11 aminoterminal residues of the crystallized CTR ECD construct do not have any difference electron density. A potential functional role of the flexible N-terminal region of the CTR ECD is not easy to predict based on the structures alone.
Several studies using cross-linking by incorporation of photolabile p-benzoyl-L-phenylalanine (BPA) residues in hCT and sCT have been published. This was done for hCT (agonist), at positions 8, 16, and 26 (27, 28) , as well as sCT (agonist) at position 19, and sCT(8 -32) (antagonist) at position 8 (29, 30) . The results show at which residues of the CTR the BPA substituted amino acid residues from these peptides cross-link upon binding. The BPA in position 26 of hCT was shown to cross-link with Thr 30 of CTR, which is positioned in the flexible aminoterminal region of the ECD not resolved in the present crystal structure. This particular proximity would require that the flexible N-terminal part of the CTR ECD folds back toward the C-terminal part of sCT in a somewhat surprising orientation. Another interesting cross-link resulted from BPA in position 8 (31)). This crude hybrid model of sCT (8 -32) nicely accounts for the distances and cross-link and represents an inactive conformation given that sCT (8 -32) is an antagonist (Fig. 5b) . In contrast, BPA in position 8 of the agonist hCT forms a cross-link to the third extracellular loop (ECL3) of CTR indicating a conformational difference between inactive and active states as previously suggested (30) . BPA in positions 16 (hCT) and 19 (sCT) cross-link with residues at the carboxyl-terminal part of the CTR ECD (Phe 137 and the fragment Cys 134 -Lys 141 , respectively), which is not easy to reconcile with the cross-link of the antagonist BPA 8 -sCT (8 -32) and therefore also support a conformational difference between inactive and active states.
The recent structures of the ligand-bound CGRP and AM receptor ECDs together with the structure of the ligand-bound CTR ECD presented here give a more advanced understanding of how the structure and sequence of the carboxyl-terminal part of the ligands are involved in receptor binding and specificity. In the calcitonin peptide family, the carboxyl-terminal amide is critical for receptor binding and the crystal structures revealed similar molecular details of this particular interaction among the different ligands and receptors. The requirement for RAMPs is linked to the nature of the residue in the most carboxyl-terminal position of the ligands. In the ligands that require RAMPs this position is occupied by either Tyr (amylin and AM) or Phe (CGRP), whereas in hCT and sCT, which do not require RAMPs this position is occupied by Pro. Assuming that the amylin receptor ECD is similar to the CGRP and AM receptor ECDs, it seems that the RAMPs do not directly prevent sCT from binding to the extracellullar domain of the amylin Table 2 . (8 -32) structure in gray schematic and surface for the ECD and yellow for the stick representation of the peptide. Hydrogen bonds likely to be conserved compared with Fig. 3b are shown as dotted lines. b, hybrid model of CTR ECD-bound antagonistic peptide sCT(8 -32) (yellow schematic) based on residues 8 -23 from a sCT NMR structure (PDB entry 2GLH) and residues 24 -32 from [BrPhe 22 ]sCT(8 -32) (chain D in this work). Residues implied in receptor interaction by cross-linking studies (Val 8 , Leu 16 , Leu 19 , and Asn 26 ) are shown with side chains represented in red sticks. CTR ECD (Chain A) is shown as a gray schematic with a transparent surface and residues Met 49 and Thr 138 are shown as blue sticks marking sites of interactions on the CTR as determined by cross-linking studies.
receptor. The binding and functional properties of the RAMP-CTR heterodimers support this observation by showing that sCT maintains high affinity and potency in the presence of RAMPs and therefore a primary effect of the RAMPs is to increase affinity and potency for amylin as suggested previously (23, 33, 37) . Fig. 6 shows a comparison of the carboxyl-terminal parts of [BrPhe 22 ]sCT (8 -32) , CGRP analogue (PDB entry 4RWG), and AM (PDB entry 4RWF) and their receptor ECDs superimposed, including the RAMP-1 and RAMP-2 ECDs. The carboxyl-terminal residues of the CGRP and AM analogues, Phe and Tyr, respectively, make perpendicular stacking interactions with the CLR ECD Trp 72 side chain (corresponding to Trp 79 in CTR ECD). The stacking interaction with Trp 72 is complemented by residues from the respective RAMP-1 and RAMP-2 ECDs and thereby the RAMPs may serve the role of protecting the hydrophobic elements of Phe or Tyr side chains from solvent exposure. The RAMPs of the amylin receptor may accommodate the carboxyl-terminal tyrosine amide residue by a mechanism similar to the RAMPs of the CGRP and AM receptors. The carboxyl-terminal proline amide residue of [BrPhe 22 ]sCT(8 -32) forms a stacking interaction with Trp 79 of the CTR ECD, which is potentially a strong interaction. The interaction energy of this kind of proline/tryptophan side chain stacking has been elucidated in a computational study and found to be ϳ7 kcal mol Ϫ1 , despite the fact that only one of the components has an aromatic character (34) . It is also illustrated by the decreased binding affinity of [Tyr 32 ]sCT(8 -32) compared with sCT(8 -32) caused by substituting the proline amide residue at position 32 by a tyrosine amide residue. Decrease in binding is seen for full-length CTR binding in whole cell competition binding for [Tyr 32 ]sCT(8 -32) ( Fig. 4 ) and for the CTR ECD bead-based assay binding could not be determined. The carboxyl-terminal tyrosine amide residue of amylin appears critical for both the low affinity of amylin for binding to CTR and the high affinity of amylin for binding to the amylin receptor.
The structures of the ligand-bound CTR, CGRP, and AM receptor ECDs enable a prediction of potential structural rearrangements induced by the RAMPs on the CTR ECD of the amylin receptor (RAMP-1/CTR and RAMP-3/CTR) and how that might affect the ligand binding properties of the CTR and amylin receptor ECD. Structural alignment of the CTR ECD PDB entry 4RWG) binding to their respective receptor ECDs. a, peptide ligands are displayed as colored schematics with the carboxyl-terminal amide residues in stick representation. Selected side chains from the receptor ECD are displayed in stick representation in the color belonging to the respective peptide and the ECD schematics are displayed in gray with darker gray for the RAMP-1 and RAMP-2 ECDs in PDB 4RWF and 4RWG complexes, respectively. In b-d one complex at the time is shown and here the colors of the peptide sticks follow their respective receptor ECD. and the CGRP receptor ECD suggests that RAMP-1 has a direct impact on the structure of the CTR ECD, specifically related to Arg 126 (Arg 119 in the CGRP and AM receptors) in the receptor loop just above the ligand (residues 121-126 of CTR). In the CTR complex, Arg 126 adopts a position remote from the ligand, whereas in the CGRP receptor complex, Phe 83 of RAMP-1 induced another conformation of Arg 119 , which thereby moves into close proximity of the ligand (Fig. 6, b and c) . In the AM receptor complex, where RAMP-2 is the binding partner, Arg 119 assumes a third conformation because RAMP-2 has a glycine in position 110, which due to the lack of side chain does not interfere with Arg 119 unlike Phe 83 of RAMP-1. Comparing the structures of the CGRP and AM receptor ECDs shows that the conformation of Arg 119 has a direct impact on the ligands causing a ϳ1.5-Å displacement of CGRP relative to AM in the binding site. In addition to the direct effect on the side chain conformation of Arg 119 , Phe 83 of RAMP-1 also causes a subtle shift of the entire receptor loop (CLR(114 -119) and CTR(121-126)). Assuming the overall structure of the amylin receptor ECD is similar to the structures of the CGRP and AM receptor ECD, Phe 83 of RAMP-1 or the corresponding Tyr 83 of RAMP-3 probably drive Arg 126 of the CTR ECD into a conformation similar to that of Arg 119 of the CGRP receptor complex, which may assist binding of amylin to its receptor. The type II turn of [BrPhe 22 ]sCT (8 -32) bound to the CTR ECD has a Gly in position iϩ2 (Gly 30 ), which is typical of type II turns. CGRP, AM, and amylin have different residues in the corresponding position of the turn sequence and specifically amylin has an Asn in this position, which is a favored residue of type I turns (see sequence alignment in Fig. 1c ). These structural observations suggest that the carboxyl-terminal part of amylin assumes a type I turn conformation upon binding to the amylin receptor similar to the receptor-bound structure of the CGRP analogue.
In summary, the available crystal structures of this Class B GPCR subfamily together with the peptide sequences and the in vitro receptor pharmacology, suggest that those peptides that require RAMPs: amylin, CGRP and AM, form a type I turn upon binding to their cognate receptor, whereas sCT and probably also hCT, which do not require RAMPs, form a type II turn upon binding to the calcitonin receptor. The requirement for RAMPs for high affinity binding of amylin may result from both a direct structural effect of the RAMP on the CTR ECD enabling a favorable interaction with the type I turn conformation of amylin and also a solvent protective effect of the RAMPs on the carboxyl-terminal tyrosine amide of amylin. 
